200 related articles for article (PubMed ID: 22336588)
1. Increased apoptosis in cancer cells in vitro and in vivo by ceramides in transferrin-modified liposomes.
Koshkaryev A; Piroyan A; Torchilin VP
Cancer Biol Ther; 2012 Jan; 13(1):50-60. PubMed ID: 22336588
[TBL] [Abstract][Full Text] [Related]
2. Selective induction of apoptosis in MCF7 cancer-cell by targeted liposomes functionalised with mannose-6-phosphate.
Minnelli C; Cianfruglia L; Laudadio E; Galeazzi R; Pisani M; Crucianelli E; Bizzaro D; Armeni T; Mobbili G
J Drug Target; 2018 Mar; 26(3):242-251. PubMed ID: 28795851
[TBL] [Abstract][Full Text] [Related]
3. Enhanced Cytotoxicity of Folic Acid-Targeted Liposomes Co-Loaded with C6 Ceramide and Doxorubicin: In Vitro Evaluation on HeLa, A2780-ADR, and H69-AR Cells.
Sriraman SK; Pan J; Sarisozen C; Luther E; Torchilin V
Mol Pharm; 2016 Feb; 13(2):428-37. PubMed ID: 26702994
[TBL] [Abstract][Full Text] [Related]
4. Transferrin and octaarginine modified dual-functional liposomes with improved cancer cell targeting and enhanced intracellular delivery for the treatment of ovarian cancer.
Deshpande P; Jhaveri A; Pattni B; Biswas S; Torchilin V
Drug Deliv; 2018 Nov; 25(1):517-532. PubMed ID: 29433357
[TBL] [Abstract][Full Text] [Related]
5. Transferrin coupled vesicular system for intracellular drug delivery for the treatment of cancer: development and characterization.
Vaidya B; Vyas SP
J Drug Target; 2012 May; 20(4):372-80. PubMed ID: 22339366
[TBL] [Abstract][Full Text] [Related]
6. A stabilized retro-inverso peptide ligand of transferrin receptor for enhanced liposome-based hepatocellular carcinoma-targeted drug delivery.
Tang J; Wang Q; Yu Q; Qiu Y; Mei L; Wan D; Wang X; Li M; He Q
Acta Biomater; 2019 Jan; 83():379-389. PubMed ID: 30395963
[TBL] [Abstract][Full Text] [Related]
7. DOPA-based paclitaxel-loaded liposomes with modifications of transferrin and alendronate for bone and myeloma targeting.
Chang Q; Geng R; Wang S; Qu D; Kong X
Drug Deliv; 2016 Nov; 23(9):3629-3638. PubMed ID: 27749106
[TBL] [Abstract][Full Text] [Related]
8. Very long chain ceramides interfere with C16-ceramide-induced channel formation: A plausible mechanism for regulating the initiation of intrinsic apoptosis.
Stiban J; Perera M
Biochim Biophys Acta; 2015 Feb; 1848(2):561-7. PubMed ID: 25462172
[TBL] [Abstract][Full Text] [Related]
9. Intracellular delivery of ceramide lipids via liposomes enhances apoptosis in vitro.
Shabbits JA; Mayer LD
Biochim Biophys Acta; 2003 May; 1612(1):98-106. PubMed ID: 12729935
[TBL] [Abstract][Full Text] [Related]
10. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin.
Li X; Ding L; Xu Y; Wang Y; Ping Q
Int J Pharm; 2009 May; 373(1-2):116-23. PubMed ID: 19429296
[TBL] [Abstract][Full Text] [Related]
11. Targeting of Micelles and Liposomes Loaded with the Pro-Apoptotic Drug, NCL-240, into NCI/ADR-RES Cells in a 3D Spheroid Model.
Pattni BS; Nagelli SG; Aryasomayajula B; Deshpande PP; Kulkarni A; Hartner WC; Thakur G; Degterev A; Torchilin VP
Pharm Res; 2016 Oct; 33(10):2540-51. PubMed ID: 27351426
[TBL] [Abstract][Full Text] [Related]
12. Enhanced therapeutic efficacy of LHRHa-targeted brucea javanica oil liposomes for ovarian cancer.
Ye H; Liu X; Sun J; Zhu S; Zhu Y; Chang S
BMC Cancer; 2016 Oct; 16(1):831. PubMed ID: 27793127
[TBL] [Abstract][Full Text] [Related]
13. Cancer-selective targeting and cytotoxicity by liposomal-coupled lysosomal saposin C protein.
Qi X; Chu Z; Mahller YY; Stringer KF; Witte DP; Cripe TP
Clin Cancer Res; 2009 Sep; 15(18):5840-51. PubMed ID: 19737950
[TBL] [Abstract][Full Text] [Related]
14. Targeting of lysosomes by liposomes modified with octadecyl-rhodamine B.
Koshkaryev A; Thekkedath R; Pagano C; Meerovich I; Torchilin VP
J Drug Target; 2011 Sep; 19(8):606-14. PubMed ID: 21275828
[TBL] [Abstract][Full Text] [Related]
15. Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma.
Stover TC; Sharma A; Robertson GP; Kester M
Clin Cancer Res; 2005 May; 11(9):3465-74. PubMed ID: 15867249
[TBL] [Abstract][Full Text] [Related]
16. Nanoliposomal ceramide prevents in vivo growth of hepatocellular carcinoma.
Tagaram HR; Divittore NA; Barth BM; Kaiser JM; Avella D; Kimchi ET; Jiang Y; Isom HC; Kester M; Staveley-O'Carroll KF
Gut; 2011 May; 60(5):695-701. PubMed ID: 21193455
[TBL] [Abstract][Full Text] [Related]
17. Anti-cancer activity of doxorubicin-loaded liposomes co-modified with transferrin and folic acid.
Sriraman SK; Salzano G; Sarisozen C; Torchilin V
Eur J Pharm Biopharm; 2016 Aug; 105():40-9. PubMed ID: 27264717
[TBL] [Abstract][Full Text] [Related]
18. Screening and optimization of ligand conjugates for lysosomal targeting.
Meerovich I; Koshkaryev A; Thekkedath R; Torchilin VP
Bioconjug Chem; 2011 Nov; 22(11):2271-82. PubMed ID: 21913714
[TBL] [Abstract][Full Text] [Related]
19. Synergistic targeted delivery of payload into tumor cells by dual-ligand liposomes co-modified with cholesterol anchored transferrin and TAT.
Tang J; Zhang L; Liu Y; Zhang Q; Qin Y; Yin Y; Yuan W; Yang Y; Xie Y; Zhang Z; He Q
Int J Pharm; 2013 Sep; 454(1):31-40. PubMed ID: 23850793
[TBL] [Abstract][Full Text] [Related]
20. A targeting drug delivery system for ovarian carcinoma: transferrin modified lipid coated paclitaxel-loaded nanoparticles.
Li R; Zhang Q; Wang XY; Chen XG; He YX; Yang WY; Yang X
Drug Res (Stuttg); 2014 Oct; 64(10):541-7. PubMed ID: 24443309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
